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Video abstract

Abstract: Lipid–polymer hybrid nanoparticles (LPHNPs) are next-generation core–shell
nanostructures, conceptually derived from both liposome and polymeric nanoparticles (NPs),
where a polymer core remains enveloped by a lipid layer. Although they have garnered significant
interest, they remain not yet widely exploited or ubiquitous. Recently, a fundamental transformation has occurred in the preparation of LPHNPs, characterized by a transition from a two-step
to a one-step strategy, involving synchronous self-assembly of polymers and lipids. Owing to
its two-in-one structure, this approach is of particular interest as a combinatorial drug delivery
platform in oncology. In particular, the outer surface can be decorated in multifarious ways for
active targeting of anticancer therapy, delivery of DNA or RNA materials, and use as a diagnostic
imaging agent. This review will provide an update on recent key advancements in design, synthesis, and bioactivity evaluation as well as discussion of future clinical possibilities of LPHNPs.
Keywords: lipid–polymer hybrid nanoparticle, lipid-based nanoparticle, polymer-based
nanoparticles, drug delivery, gene delivery
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Nanotechnology is a compelling medicinal platform with the potential to greatly impact
the delivery of a plethora of therapeutics, encompassing small molecule therapeutics,
genes, RNAs, peptides, and diagnostic imaging agents, as well as holding great promise for improving the therapeutic index and pharmacokinetics of several drugs under
systemic settings.1–4 In general, these payloads are encapsulated within or covalently
grafted on the surface of the nanocarriers, and after being systemically incorporated,
their release is monitored by factors such as formulation of the matrix, pH of the
microenvironment, and temperature of the surroudings.5–7 The inherent potential of
nanoparticles (NPs) for therapeutic cargo delivery is primarily attributable to few key
parameters, including average nanometric size, homogeneity, surface potential, and
drug loading, among others.8,9 Surface-coated immuno-inert NPs can also skillfully
bypass the reticuloendothelial system yielding increased bioavailability of encapsulated drugs.10 The plausible advantages of nanocarriers are summarized as follows:
1) improvement to a drug’s overall pharmacokinetic and pharmacodynamic properties
without alteration of its molecular structure; 2) enhanced effective tissue targeting,
cellular targeting, and molecular targeting; 3) the ability to circumvent many inherent
biological impediments; 4) targeted and nontargeted drug delivery to their respective site of action (cytosol, nucleus, etc) and enhanced therapeutic index of the drug;
5) delivery of multiple drugs with differing chemical properties.11,12
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In the last few decades, an increasing amount of
nanotechnology-based products have begun clinical trials –
including liposomes, polymeric NPs, albumin NPs, and inorganic NPs – of which a small number have already been
accepted for clinical use.13–17 Among these nanocarrier types,
the two best characterized are liposomes and polymeric NPs.
Liposomes are artificial “fat bubbles”, ie, vesicles, characterized by having one or more bilayers spontaneously
achieved by dispersal of natural or synthetic amphiphatic
lipids in water. Since their discovery, they have largely been
exploited as delivery vehicles because of their biocompatibility and advantageous safety profile. Their surface can be
modified by attaching polyethylene glycol (PEG) which, in
turn, prolongs circulation half-life.18,19 Doxil and Myocet,
two leading doxorubicin liposomes, received Food and Drug
Administration (FDA) approval in 1995 and 1999, respectively, followed later by others of the same category.20 To
date, around 16 liposomal drugs are clinically approved and
a few of those are marketed, such as AmBisome (amphotericin B), DaunoXome (daunorubicin), DepoCyt (cytarabine),
DepoDur (morphine), and Visudyne (verteporfin).15 Despite
clinical approval, until recently no FDA-approved liposomal
drugs showed significant overall survival (OS) improvement
over the parent drug.21 In a 2017 study, phase III outcomes of
liposomal combination drugs such as cytarabine–daunorubicin (Vyxeos; CPX-351), as contrasted with their individual
counterpart cytarabine and daunorubicin (“7+3”) in 60- to
75-year-old patients with high-risk acute myeloid leukemia,
revealed enhanced OS of 9.56 vs 5.95 months.22
Polymeric NPs, on the contrary, can be manufactured (via
nanoprecipitation or the double emulsion method) by selfassembly of biodegradable amphiphilic block copolymers
with varying hydrophobicities and are appropriate for systemic administration. The core–shell structure of polymeric
NPs facilitates encapsulation of hydrophobic drugs and
sustained drug release and extends circulation time. Their
surfaces can also be decorated with ligands for targeted drug
delivery.23,24 For instance, Genexol-PM is a polymer-based
NP formulation of paclitaxel (PCX) and poly (d,l-lactide)b-polyethylene glycol-methoxy (PLGA-mPEG), which has
been approved for metastatic breast cancer therapy in Korea
and the European Union.25,26
In order to utilize the unique attributes of liposomes and
polymeric NPs that led to their initial clinical success, but
overcome limitations like structural disintegration, limited
circulation time, and content leakage, a new progeny of
delivery system has been developed: lipid–polymer hybrid
nanoparticles (LPHNPs).27 The hybrid system can be a sturdy
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drug delivery rostrum with high encapsulation efficiency,
well-defined release kinetics, well-tolerated serum stability,
and well-triggered tissue, cellular, and molecular targeting properties. In this article, we will review the emerging
innovations of LPHNPs, incorporating new developments
in their production strategies and drug delivery applications
in cancer therapy.

Structure elucidation and mechanism
of hybrid formation
As can be inferred from their name, LPHNPs merge the
features of both polymeric NPs and liposomes. They consist
of three building blocks as illustrated in Figure 1. These are
1) a polymer core encapsulating the drug, 2) a lipid monolayer surrounding the polymer core, and 3) an outer lipid–
PEG layer, a steric stabilizer prolonging systemic circulation
of the LPHNPs by evading immune destruction. The middle
lipid monolayer behaves like a molecular barricade that
mitigates the loss of entrapped drugs over the course of the
LPHNP formulation and protects the core from degradation
by preventing the diffusion of water into the inner core.27,28
The molecular mechanics of fusion between lipid and
polymer is still under investigation. It is apparent that distinguished methods of LPHNP manufacturing have different mechanisms of formation. For instance, in single-step
methods, the polymer precipitates from the organic solvent
when added to aqueous media containing lipids, which
subsequently spontaneously self-assemble into a monolayer
surrounding the core. PEGylated lipids also self-assemble
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Figure 1 Structure of a lipid–polymer hybrid nanoparticle (LPHNP) comprises of
a polymer core encapsulating a pay load, a lipid shell, and an outer lipid–PEG layer.
Note: The lipid–PEG layer can also be conjugated to a variety of targeting agents,
such as folic acid, arginylglycylaspartic acid (RGD), or antibodies, to ensure
targeted delivery.
Abbreviation: PEG, polyethylene glycol.
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during this step, wherein a lipid moiety clings onto the surface
of the polymer core and the PEG chain extends externally
toward the aqueous environment. During the two-step
method, a plausible mechanism of LPHNP formation may
involve an initial bilayer structure formation and adherence
to the core, with subsequent disintegration of the bilayer
owing to the hydrophobic interaction between polymer and
lipid chains. The hybrid formation is thermodynamically
favorable, with respect to hydrophobic, van der Waal, and
electrostatic interactions.29,30

Methods for preparation of LPHNPs
Two-step method
Conventional method

During initial days of study, a typical two-step method was
frequently employed to form LPHNPs, wherein preformed
polymeric NPs were mixed with preformed lipid vesicles and
the latter was surface-assimilated onto the former, propelled
by electrostatic forces. The polymeric NPs are generally
prepared by nanoprecipitation,31 emulsification–solvent
evaporation (ESE),32 or high-pressure homogenization.33
As depicted in Figure 2, the two-step method can be subcategorized into two types: A) direct addition of the previously
formed polymeric NPs to dried lipid film, or B) preformed
NPs added to preformed lipid vesicles, made by initial

hydration of the thin lipid film. In either case, the hybrids
are assembled by the input of external energy via vortexing
and/or ultrasonication of the suspension and heating at a
temperature beyond the phase transition temperature of the
lipid constituent. In purification step, free lipid and LPHNPs
are separated by differential centrifugation. For instance,
a method was developed for hybrid NP preparation using
PLGA combined with cationic lipid vesicles (FA-OQLCS/
PEG-OQLCS/Chol) under continuous stirring or bath sonication at 30°C, yielding stable LPHNPs with average sizes
between 200 and 400 nm and a surface potential of (+)
20–30 mV.32,34 Using different precursors, Thevenot et al and
Troutier et al utilized a similar method to make LPHNPs.31,35
In order to obtain a homogeneous NP suspension with
unimodal particle distribution, hybrid NPs undergo sequential
extrusion and/or homogenization after preparation. While
extruding the sample, as normally practiced in the laboratory,
the NP suspension is downsized by passing them through
a porous membrane. For example, Messerschmidt et al
created tumor necrosis factor (TNF)-functionalized hybrid
NPs using polystyrene as the core and shell made up of egg
phosphatidylcholine (egg-PC), cholesterol, DSPE–mPEG,
and maleimide-DSPE–mPEG. The resultant NPs were downsized by extruding through a 200 nm porous membrane.36
This technique was also employed by Hu et al to construct

Hydration with
aqueous solvent
Preformed lipid
vesicles
Aqueous
polymeric
nanoparticle
suspension

Formation of
lipid vesicles

B

Thin lipid film

A

Aqueous
polymeric
nanoparticle
suspension

Thin lipid film

Homogenization:
ultrasonication,
vortexing, etc

Lipid polymer
nanoparticles

Polymeric nanoparticle
Figure 2 The two versions of lipid–polymer hybrid nanoparticle preparation via the two-step method.
Notes: (A) The aqueous polymeric nanoparticle suspension is directly added to the dried lipid film. (B) Thin lipid film is first hydrated with an aqueous solvent to facilitate
the formation of lipid vesicles. The hydrated vesicles are then combined with an aqueous preformed nanoparticle suspension. For either technique, the hybrids are then
produced via vortexing or ultrasonication of the mixture at a temperature greater than the phase transition temperature of the lipids.
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a red blood cell membrane-coated NPs (~120 nm) and
by Sengupta et al to produce chemotherapeutic LPHNPs
(~200 nm).37,38 As a substitute, some other groups explored
homogenization to formulate unimodal LPHNPs (~60 nm)
made up of a maltodextrin polysaccharide core and a DPPC/
Chol lipid shell.33,39

Nonconventional method
Aside from the abovementioned methodologies, few other
methods going beyond convention have also been implemented to manufacture LPHNPs. For example, polymeric
NPs (ie, polyglutamic acid, polylysine) of average size
400–500 nm were produced by spray drying, dispersed in
DCM containing the lipids (tripalmitin, tristearin, cetyl alcohol). This suspension was later spray-dried again to prepare
LPHNPs of size range 0.9–1.2 µm with aspray dryer that
was inappropriate for the production of NPs.40 The recently
marketed nanometric spray dryer can be used to produce
smaller hybrid NPs as well.41
Additionally, in recent years, a particle molding method
by soft lithography called particle replication in nonwetting
templates (PRINT) was explored to prepare LPHNPs for the
delivery of genetic materials.42

Optimization of formulation parameters
The physical characteristics of LPHNPs (average size, colloidal stability, polydispersity) prepared by the two-step
method are majorly regulated by the following formulation
parameters: 1) preformed lipid vesicle size and polydispersity index (PDI), 2) surface potential of the outer lipid shell,
3) ionic strength of the aqueous phase, 4) lipid-to-polymer
ratio, and 5) PEG chain length and mol% of PEG–lipid.31,35 In
particular, extrusion-produced particles are smaller and more
homogeneous compared with that generated by direct lipid
film hydration with polymer solution. Moreover, homogeneity of LPHNPs is critically dependent on the charge of the
lipid vesicles. As such, least particle aggregation with high
colloidal stability and narrow PDI was attained by using only
one lipid type to form the vesicles, ie, only the zwitterionic
lipid DPPC or the cationic lipid DPTAP. On the contrary,
aggregation-prone LPHNPs have been formed when both
DPTAP and DPPC were used, the mechanism of which
could be attributed to the electrostatic interactions between
the two types of lipids.35 Separately, hybrid particles’ colloidal stability was notably impacted by lipid to polymer ratio
(AV/AP). At high lipid to polymer AV/AP and high cationic
lipid concentration, the lipid layer may potentially act as
electrostatic stabilizer. At low AV/AP and low fractions of
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cationic lipid, partial lipid coating of the polymer core was
insufficient to stabilize the LPHNP. The anionic surface of
the core of one hybrid molecule was exposed to the cationic
DPTAP of another hybrid leading to the agglomeration of
LPHNPs. Intriguingly, with DPPC alone, the hybrid NPs
were less susceptible to agglomeration even at low AV/AP.
This can again be credited to the zwitterionic nature of DPPC
reducing the possibility of electrostatic interactions.35
Similar to liposomes, a drawback of LPHNPs is their
weak colloidal stability relative to the ionic strength of the
solution; electrostatic interactions alone cannot stabilize
hybrid particles in aqueous medium with .10 mM NaCl
ionic strength. Again, like liposomes, this is mitigated by
incorporating conjugated PEG–lipids into the lipid mixture
(DPPC/DPTAP) to impart stabilizing PEG chains onto the
surfaces of the LPHNP. To envisage the most advantageous conditions to attain colloidal stability, Thevenot
et al thoroughly investigated the effects of the PEG chain
length (n=16, 45, and 113) and mol% (1%, 5%, and 10%) of
PEG–lipid in lipid formulation, where the polymer core was
made up of PLA and lipid layers were comprised of DPTAP,
DPPC, and PEG–phosphoethanolamine (PEG–PE). Keeping
the lipid composition unchanged (DPPC:DPTAP:PEG–
PE=40:50:10% w/w), and upon gradual increase in the degree
of polymerization in the PEG chain, they observed that the
mol% of the PEG–lipid inhabiting the lipid shell decreased
with stretching chain length from ~3% for n=16 and 45 to
~2% for n=113. The observation was ascribed to spatial repulsion between the bulky lipid–PEG shells with longer PEG
chains. Importantly, thickness of the lipid layer adsorbed onto
PLA particles was increased with the amount of PEG–lipids
adsorbed or with the PEG chain length, from 67 Å at n=16 to
98 Å at n=113. This resulted in an increased charge screening
effect, which subsequently lowered the zeta potentials from
(+) 51 mV at n=16 to (+) 22 mV at n=113. This is owed to
a transition from mushroom-like confirmation to outward
brush-like confirmation. In accordance with the quasi-elastic
light scattering (QELS) study, the n=16 PEG shell was not
adequate enough to be effectively sterically stabilizing. The
n=45 PEG shell showed moderate stabilization, while the
n=113 PEG shell displayed the best colloidal stability for the
hybrid NPs. Thickness of the lipid shell increased from ~52
Å at 1% PEG–PE to 79 Å at 10% PEG–PE, and this lowered
the zeta potentials from (+) 47 to (+) 26 mV, respectively.31
Apart from average size, PDI, and surface potential
(which is a measure of colloidal stability), other important formulation parameters are % drug loading (%DL),
% encapsulation efficiency (%EE), and in vitro release
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kinetics of the drug from the LPHNPs. For example,
Mieszawska et al demonstrated an %EE =85% w/w and
%DL =11% w/w for their anticancer drug.32 Hasan et al
also showed an %EE =32%–46% w/w for siRNA using
the PRINT method.42 This is worth mentioning because
for LPHNPs prepared by the two-step method, %EE of the
drug is majorly determined by the formulation parameters
of the polymeric core, which has been extensively explored
in previous studies; similar trends are followed when the
same polymer was used for the LPHNP formation.43

One-step method
The limitation of the two-step method is that preparing
polymeric NPs and lipid vesicles separately makes the
process inefficient in terms of energy and time spent. The
commonly available and more efficient alternative is a onestep method. Preformed lipid vesicles and polymeric NPs
are not prerequisites for the one-step method. The method
solely requires mixing of lipid and polymer solutions that
subsequently tend to self-assemble to form LPHNPs. The
most common processes are nanoprecipitation and/or ESE,
both of which are often implemented for the production of
nonhybrid polymeric NPs. Here, the lipids/PEG–lipids used
function as stabilizing agents for the hybrid produced, while
ionic or nonionic surfactants (PVA, DMAB, poloxamer) are
generally used as stabilizers in the preparation of regular,
nonhybrid polymeric NP.

Nanoprecipitation
Traditional nanoprecipitation method requires that the drug
and polymer are dissolved together in a water-miscible
organic solvent (viz, acetone, EtOH) and the lipid/lipid–PEG
dissolved in water. It is mandatory to heat the lipid/lipid–PEG
solution beyond its gel-to-liquid transition temperature in
order to achieve a homogeneously dispersed liquid crystalline
phase. This is followed by drop wise addition of the polymer
to the aqueous dispersion of lipid under continuous stirring.
This triggers the polymer to coil into NPs with concurrent
self-assemblage of the lipids surrounding the polymer owing
to hydrophobic interactions, where hydrophobic tails of the
lipids are directed toward the inner NP and the hydrophilic
head groups face out toward the external aqueous solution.
The hydrophobic lipid tails of the lipid–PEG merge into the
inner lipid shell, while its PEG chains pop out to the aqueous
environment, sterically stabilizing the hybrid.27 The organic
media is evaporated and the LPHNPs, thus formed, are
centrifuged (Figure 3). A promising noninvasive delivery
of mRNA-based vaccines, developed recently, involves
postinsertion of the PEGylated lipid vesicles following
nanoprecipitation.44
A few novel approaches are being adopted by a number
of research groups to improve upon one-step methods.
For example, using a bath sonication approach, Fang et al
demonstrated a rapid synthesis (~5 minutes) of hybrid NPs
with small and nearly uniform size.29 In 2010, Valencia et al
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Figure 3 Nanoprecipitation technique for the preparation of LPHNPs by one-step method.
Notes: Drug and polymer are dissolved together in a water-miscible solvent, such as ethanol or acetone. The lipids and/or lipid–PEG are dissolved together in water, and
the solution is heated beyond the lipids respective gel-to-liquid transition temperature. The polymer/drug solution is then added drop-wise to the lipid dispersion during
continuous stirring, triggering the precipitation of the nanoparticles and the aggregation of the lipids/lipid–PEGs around the NP core due to hydrophobic interactions.
Abbreviations: LPHNPs, lipid–polymer hybrid nanoparticles; NP, nanoparticle; PEG, polyethylene glycol.
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reported the use of microfluidics, where two phases are
rapidly mixed using hydrodynamic flow, directly generating
homogeneous NPs with relatively narrow size distribution.45
Fang et al, again in 2012, came up with a multi-inlet vortex
reactor for scale up of LPHNPs.46 To address the issues
with low throughput of microfluidics, Kim et al developed a
pattern-tunable microvortex platform for scale up of LPHNPs
as well. The microvortex platform could restrict the average
size of NP between ~30 and 170 nm with low PDI (~0.1)
and high productivity (∼3 g/hour) by varying flow rates
(ie, Reynolds number [30–150]).47

Optimization of formulation parameters in
nanoprecipitation
The unanimous formulation parameter indicated in many
studies as having the most prominent effect on the characteristics of an LPHNP is the stoichiometry, ie, the lipid to
polymer mass ratio (L/P ratio). In two consecutive studies
performed in O C Farokhzad’s laboratory, the L/P ratio
was optimized to be 15% (w/w) for optimal covering of the
polymer, where PLGA was used as the polymer and lecithin
plus DSPE–PEG as the lipids, to generate stable monodisperse LPHNPs (60–80 nm).27,48 This optimization was
crucial as higher L/P (w/w) ratios led to lipid concentrations
greater than the CMC (critical micelle concentration of the
polymer), which could lead to the formation of liposomes
in addition to hybrids, while lower L/P (w/w) ratios led
to agglomeration. Similarly, cationic LPHNPs of average
size ~65 nm were prepared by single-step nanoprecipitation
of a cationic lipid (BHEM-Chol) and amphiphilic polymer
mPEG–PLA for systemic delivery of siRNA, where optimal
L/P ratio was reported to be 10% (w/w).49 Intriguingly, as
demonstrated by Zheng et al, in the absence of lipid–PEG,
a huge excess of lipid (egg-PC/DOPE lipid shells with
D-α-TPGS) was needed in the formulation leading to an
optimum L/P ratio of 428% (PLGA-to-lipid ratio of 3.5/15),
to form hybrid NPs with relatively higher average size
(150–190 nm).50
A salient feature of the lipid coating (reflected as L/P
ratio), as discussed in structure elucidation, is to protect
the polymer core. This indirectly regulates %EE and drug
release.27 In contrast, for nonhybrid polymeric NPs, the
polymer’s physicochemical property is the sole influence
on %EE and release kinetics.51 At the optimal L/P ratio
(15% w/w), LPHNPs showed higher %EE of the docetaxel
(59%±4%) compared with its nonhybrid counterparts PLGA
NPs (37%±4%) and PEGylated-PLGA NPs (19%±3%).
A longer sustained release of the drug (50% in 20 hours)
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was shown by LPHNPs compared with that of PLGA and
PLGA-PEG NPs (50% in 7 and 10 hours, respectively).27
The colloidal stability of LPHNPs (prepared either by
one-step or two-step method) is contingent on the lipid–PEG
present in the lipid formulation. In the absence of PEGgrafted lipid, despite reasonably high L/P ratio, lecithincoated PLGA NPs were shown to be unstable when they
formed large aggregates (~2 µm) in PBS, hinting at the
inability of the lipid layer to stabilize the formulation.48 With
the addition of DSPE–PEG, the LPHNPs became stable in
PBS as the PEG chains conferred steric stabilization. By
enhancing the PEGylated lipid in the lipid formulation,
more stable hybrid NPs were yielded, where the optimal
lipid–PEG amount was found at ~25% (w/w). Importantly,
higher concentration of PEG on the particle surface did not
alter the release kinetics or %EE.48,52,53
Nonetheless, PEG fraction present in the formulation
does influence the average size of LPHNPs. For example,
according to the study performed by Zheng et al, a decrease
in the LPHNP size (from 230 to 150 nm) with increasing PEG
fraction was observed.50 Be that as it may, other formulation
parameters, viz, concentration and molecular weight of polymer, and water-to-solvent ratio have similar effects on the
size of nonhybrid polymeric NPs as well as hybrid NPs.27,48,53

Emulsification–solvent evaporation
This method can further be subclassified into single and double emulsification methods as depicted in Figure 4A and B,
respectively. A single ESE method (Figure 4A) is used for
drugs soluble in hydrophobic solvents (oil phase). In this
method, an oil-in-water (o/w) emulsion is formed when
the water-immiscible oil phase containing the polymer and
the drug is mixed with an aqueous phase containing dissolved lipid under ultrasonication or constant stirring. Next,
the polymer core is formed by evaporation of the organic
media and the lipids assemble around the polymer core
concomitantly.54 As an ostensible replacement, the lipid can
concurrently be dissolved in the oil phase with the polymer.55
A double ESE method (w/o/w) is applied for water-soluble
drugs (Figure 4B). First, the aqueous solution of the drug is
emulsified in an organic solvent (oil phase) containing polymer and lipid to form a w/o mixture. A w/o/w emulsion is
generated when the mixture is emulsified again in an aqueous
phase containing the lipid–PEG, followed by subsequent oil
phase evaporation, to yield the LPHNPs.55 As evident from
Figure 4B, the hybrids produced by the double ESE method
contain certain structural anomalies. It is composed of 1) an
inner aqueous core surrounded by lipid layer, 2) a polymer
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Figure 4 LPHNPs produced by the emulsion-solvent evaporation (ESE) method.
Notes: (A) Single ESE method utilized for a hydrophobic drug (soluble in oil phase). Water-immiscible solvent is used to dissolve drug and polymer. The resulting solution is
added to lipid/lipid–PEG containing aqueous phase under agitation to form an oil/water emulsion. The oil phase is evaporated out, along with simultaneous formation of the
polymer core and lipid shell. (B) Double ESE method is employed for hydrophilic (water-soluble) drugs. An aqueous solution of drug is emulsified in organic solvent containing
polymers and lipids, under constant stirring. This w/o emulsion is again emulsified in an aqueous solvent containing the lipid–PEG, forming a w/o/w emulsion. Evaporation of
oil phase leads to LPHNP formation.
Abbreviations: LPHNPs, lipid–polymer hybrid nanoparticles; PEG, polyethylene glycol.

layer in between, and 3) an outer lipid–PEG shell. Generally,
the ESE method produces LPHNPs that are larger than those
produced by conventional nanoprecipitation.

Optimization of formulation parameters in ESE
Resembling nanoprecipitation, L/P ratio is the most prominent among all formulation parameters to govern ESE
method. Using PLGA, TPGS, and PC, Cheow and Hadinoto
found a reduction in size with increase in L/P ratio and
achieved a standard production yield (w/w).55 Liu et al
achieved similar results with the single ESE method using
PLGA and 1,2-dilauroylphosphatidylocholine (DLPC).56
Bershteyn et al demonstrated that excess lipid in the system
(high L/P ratios) resulted in either multilamellarity of lipid
layer or spontaneous precipitation of the lipids as liposomes.54
Here also, the L/P ratio was shown to have an influence on
%EE. The optimal lipid concentration in terms of smaller
size and high %EE was 0.04% (w/v).56 Interestingly, the
ESE method typically resulted in higher %EE than that
of nanoprecipitation due to larger particles produced. For
example, polymer remaining same, nanoprecipitation yielded
%EE ~20% (w/w) for PCX in ~50–60 nm LPHNPs,48 while
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ESE method yielded %EE ~60% (w/w) in ~200–300 nm
particles.56 In 2011, a novel one-pot synthetic method was
developed for ESE. Using PLGA as the core, and either
cetyltrimethylammonium bromide or PEG–DSPE as an
emulsifier, hybrid particles of $50 nm were produced, which
also possessed high %EE.57 Cheow and Hadinoto, exploiting
fluoroquinolone antibiotics as a model, proved that ionic
interactions between the drug and the lipid are crucial in the
preparation of LPHNPs by ESE method.55

Advances in drug delivery
applications of LPHNPs
Given the large number of potential drug delivery applications that exist, there is great interest in exploring uses of the
LPHNP platform in future clinical studies. Here, we discuss
few important recent advancement made in the field and areas
of future interest.

Nontargeted combinatorial drug delivery
approach
Besides having an array of single drug delivery strategies
via LPHNPs (eg, in chemotherapy 27,48,56 and antibiotic
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treatment58–60), significant endeavors have been directed
toward development of a combinatorial approach for cancer
therapeutics. Truly effective cancer treatment regimens often
require multiple chemotherapeutic drugs used in tandem or
chemotherapeutic drugs administered in combination with
targeting therapeutic agents.61
However, a pertinent question arises as to how best to
maximize the efficacy of NP-mediated delivery of therapeutic
payload: codelivery from a single nanocarrier or two different
carriers? It has been proposed by many that a single biocompatible nanocarrier capable of carrying more than one agent
in particular stoichiometry and releasing them in a sustained
way may hold the most promise. We provide a brief account
of several strategies that have already been employed to
accomplish successful combinatorial drug delivery exploring
the potential of LPHNP platform (Table 1).
Two major obstacles of antiangiogenic cancer therapy
include 1) not allowing tumor to obtain an effective concentration of the chemotherapeutics and 2) induction of
tumor hypoxia, resulting in chemoresistance and enhanced
invasiveness. To address these issues, Sengupta et al came
up with a hybrid nanocell where the core was comprised of
DOX-conjugated PLGA and the envelope was made up of
PC-Chol-DSPE–PEG entrapping combretastatin-A4 (for
vascular closure) and validated its therapeutic efficacies in the
murine model of melanoma and Lewis lung carcinoma.37 In
2013, Zheng et al, to accomplish combined chemo-photothermal therapy, successfully synthesized PLGA-lecithin-PEG
hybrid NPs by a single-step sonication method, which could
simultaneously deliver DOX and indocyanine green (ICG)
to the tumor microenvironment. It induced apoptotic cell
death to DOX-sensitive MCF-7 or DOX-resistant MCF-7/
ADR in vitro and inhibited MCF-7 or MCF-7/ADR tumor
growth and inhibited tumor recurrence under systemic
settings.62 To surmount the immunoinhibitory property of
the tumor microenvironment, Park et al synthesized hybrid
NPs comprised of SB505124-entrapped cyclodextrins and
cytokine-encapsulating PLGA within a PC-Chol-DSPE–PEG
shell, which can simultaneously deliver both agents to the
tumor microenvironment. As reported, sustained release of
TGF-β receptor-I inhibitor and IL-2-inhibited tumor growth
significantly enhanced survival of tumor-bearing mice and
enhanced the natural killer cell activity and CD8+ T-cell
infiltration.63 In order to sensitize intrinsically (and acquired)
cisplatin-resistant tumors, Xu et al prepared a hybrid NP with
a cationic lipid-like molecule and PLGA-PEG for codelivery
of cisplatin prodrug and siRNAs targeting the REV1, REV3L
genes, which are engaged in the modification-susceptible
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translesion DNA synthesis pathway. Importantly, after a
single dose, a remarkably sustained (up to 3 days) downregulation of both the genes was measured by real-time qPCR.
Systemic administration of these NPs displayed synergistically inhibited tumor growth in a human metastatic lymph
node carcinoma of the prostate xenograft mouse model,
outcompeting Pt monotherapy.64 Again in 2013, Deng et al
designed and synthesized layer-by-layer hybrid NPs to codeliver an MRP1 siRNA that downregulates a drug-resistant
pathway and DOX to treat triple negative breast cancer in an
MDA-MB-468 xenograft model. It turned out to be a potent
combination therapy in their study, emphasizing the potential of layer-by-layer NPs as a multitherapeutic platform for
combinatorial therapy.65 In another study, to obtain improved
synergistic effect by sequential and site-specific delivery,
Jiang et al reported a nanodepot, where the core is a liposome
encapsulating DOX in the aqueous interior, and an outer
shell comprised of cross-linked hyaluronic acid entrapping
a TNF-related apoptosis-inducing ligand. Substantial tumor
growth inhibition was found in the MDA-MB-231 murine
xenograft model.66
To achieve a concurrent treatment of chemotherapy and
radiotherapy, using nanoprecipitation method, Wang et al
developed small LPHNPs named ChemoRad coencapsulating chemotherapeutic (docetaxel) in the PLGA core and
radiotherapy agents (indium-111 or yttrium-90) chelated
to a 1,2-dimyristoyl-sn-glycero-3-phosphoethanolaminediethylene-triamine-penta acetate (DMPE–DTPA) lipid
shell. As per their report, absorption of radioactive isotopes
was not detrimental toward encapsulation and release of the
drug. Within 45 minutes, particles were taken up by LNCaP
prostate cancer cells and showed enhanced cytotoxicity over
their single counterparts.67 Concurrent incorporation of two
chemotherapeutic drugs (doxorubicin and camptothecin)
into a single LPHNP system was also achieved by covalent
grafting of the drugs with the polymer. Aryal et al synthesized
DOX-PLA and CPT-PLA conjugates, adjusted their molar
ratio, and enveloped them by egg-PC-DSPE–PEG-COOH
using a nanoprecipitation method.68 In a similar way, PCXgemcitabine69 and PCX-cisplatin70 conjugates were prepared
and loaded onto LPHNPs.

Active-targeted drug delivery
In recent years, cancer research has increasingly focused on
receptor-mediated active-targeted drug delivery to decrease
off-site chemotherapy toxicities and increase drug accumulation in target tumor cells. This has been achieved by
functionalizing NPs (drug delivery systems) with the ligand
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PC/NH2-PEG–DSPE/cholesterol
PLGA/G0-C14

DSPC/cholesterol/POPG

Lecithin/DSPE–PEG/DMPE–DTPA; DSPE–PEGaptamer
DSPE–PEG; phospholipids

PLA-PEG-PLA
PLGA-PEG

Poly-l-arginine/PLA/PEI

PLGA; DSPE–
poly[ethylene glycol]
Poly-l-lactide conjugated
to drug
PLGA
PLGA
PLGA

Gemcitabine hydrochloride
Cisplatin prodrug
Yittrium-90

Camptothecin

Doxorubicin
Pacitaxel
Pacitaxel
Pacitaxel

Yttrium-90; indium-111

Doxorubicin

Docetaxel

siRNA

IL-2
Cisplatin prodrug

ICG

Combretastatin

70
~70
~75

100

65

120

120
180–220

~86.3

80–120

Size (nM)

N/A
0.21
N/A

0.17

N/A

0.08–0.12

0.2
0.23

0.106

N/A

PDI

MDA-MB-435
XPA3
A2780
SKOV3, SW626
xenograft mice

-53
N/A
-35

BL6/F10 melanoma/
Lewis lung carcinoma
xenograft C57/B16 mice
MCF-7 or MCF-7/
ADR xenograft nude
mice
B16/B6 mouse model
LNCaP xenograft
mouse model
MDA-MB-468; NCR
nude mice
LNCaP; PC3

Cell/animal

-47

35

-55

~0
15–25

-21.71

N/A

Zeta
potential
(mV)

69
70
74

68

67

65

63
64

62

37

Ref.

Abbreviations: DMPE–DTPA, 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine–diethylene-triamine-penta acetate; ICG, indocyanine green; LPHNPs, lipid–polymer hybrid nanoparticles; PDI, polydispersity index; PEG, polyethylene
glycol.

Lecithin/DSPE–PEG-COOH
Lecithin + DSPE–PEG-COOH
(Lecithin + DMPE–DTPA)/(DSPE–PEG + DSPE–
PEG-folate)

Doxorubicin

Lecithin + DSPE–PEG

PLGA

SB505124
siRNA

Doxorubicin

PEG–DSPE/phosphatidylcholine/cholesterol

PLGA

Drug(s)

Lipid

Polymer

Table 1 Examples of combinatorial delivery approaches by LPHNPs
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Table 2 Examples of targeted delivery approaches by LPHNPs
Polymer

Lipid

Targeting
ligand

Drug

Size
(nM)

PDI

Zeta
potential
(mV)

Cell/animal

Ref.

PLGA

Lecithin/PEG2000/DSPE–PEG2000FA

Folate

Doxorubicin HCl

118

0.12

-8.5

72

PLGA

DLPC/DSPE–PEG2000/DSPE–
PEG2000-FA
PEG/DSPE–PEG2000/DSPE–
PEG2000-FA
DSPE–PEG2000/lecithin/DSPE–
PEG2000-FA
Lecithin/DSPE–PEG-COOH/
DSPE–PEG2000-FA
SPC/DPPE/DSPE–PEG-COOH/
DSPE–PEG2000-FA
EPC/DSPE–PEG/DSPE/H2NPEG2K-OH
Lecithin/cholesterol/Chol-PEGRGD
Lecithin/DSPE–PEG2000-Mal

Folate

Docetaxel

263.6

0.16

-20.74

Folate

Pacitaxel

279.9

0.173

-17.5

Folate

Cisplatin; ICG

90–100

0.2

-19.8

KB; COS-7;
KB xenograft
mice
MCF-7;
NIH/3T3
EMT6
xenograft mice
MCF-7

Folate

Doxorubicin

118.7

0.104

15.19

MCF-7

77

Folate

Mitomycin C

215.6

0.145

-25.88

78

RGD

10-Hydroxycamptothecin

249

0.289

-25.6

RGD

Curcumin

216.6

0.205

-0.23

HeLa; A549;
H22 tumor rats
MDA-MB435s; MCF-7
B16; HUVEC

RGD

Isoliquiritigenin

137.2

N/A

-34.2

81

Lecithin/DSPE–PEG2000-OMe/
DSPE–PEG2000-RGD

RGD

Docetaxel

110

0.132

-25.67

MDA-MB-231;
MCF-7; 4T1
xenograft mice
C6; GBM
bearing rats

PCL-PEGPCL
PLGA
PLGA
PLA
PLGA
mPEGPLGA
PLGACOOH
PLGA

73
75
76

79
80

82

Abbreviations: DLPC, 1,2-dilauroylphosphatidylocholine; ICG, indocyanine green; LPHNPs, lipid–polymer hybrid nanoparticles; PCL–PEG–PCL, poly(ε-caprolactone)–
poly(ethylene glycol)–poly(ε-caprolactone); PDI, polydispersity index; PEG, polyethylene glycol.

(targeting moieties) for a particular receptor (eg, folate,
integrin, transferrin) overexpressed in specific cancer
cells.71 In the following section, we will discuss different
methods utilized for surface modification followed by active
targeting (Table 2).

Folate-mediated delivery
In 2015, Wu et al synthesized a reduction-sensitive biodegradable hybrid NP, targeted with a folate ligand, to deliver
DOX. The NP was comprised of a PLGA core, a soybean lecithin and monomethoxy-poly(ethylene glycol)-S-S-hexadecyl
(mPEG-S-S-C16) monolayer, and DSPE–PEG-folate and
prompted a faster release of DOX in the presence of 10 mM
dithiothreitol. Owing to receptor-mediated endocytosis, these
particles enhanced cellular uptake and cytotoxicity in folateoverexpressing human oral cavity squamous carcinoma
cells (KB cells) and showed greater tumor accumulation
and appreciable antitumor efficacy in KB cells xenografted
into BALB/c nude mice.72 Folic acid was also selected as
a ligand for targeted delivery of docetaxel to certain breast
cancer and ovarian cancer cells by Liu et al in 2010, where
their LPHNP was composed of a PLGA core, DLPC to
envelop, DSPE–PEG2000 for stealth and DSPE–PEG5000folate for active targeting. NPs were tuned for stoichiometric
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management of the targeted delivery, were stable with desired
surface property, and showed long half-life in plasma.73 With
a view to harness a combined outcome of chemotherapy and
radiotherapy, another folate-decorated LPHNP was designed
by Werner et al and synthesized using nanoprecipitation technique to simultaneously encapsulate PCX and yittrium-90.
Monodisperse hybrid NP contains a PLGA core and a
shell of soybean lecithin, DMPE–DTPA, DSPE–PEG, and
DSPE–PEG-folate. From in vivo efficacy studies using an
ovarian peritoneal metastasis model, it is clearly evident that
folate-targeted NPs containing dual chemoradiotherapeutics
were noticeably more effective compared with nontargeted
and single drug NPs.74 In 2015, using a thin-film hydration
and ultrasonic dispersion method, Zhang et al prepared PCXloaded LPHNPs with a poly(ε-caprolactone)–poly(ethylene
glycol)–poly(ε-caprolactone) (PCL-PEG-PCL) core, DSPE–
PEG2000 corona, and DSPE–PEG2000-folate active targeting
ligand. In BALB/c mice bearing EMT6 (mammary carcinoma cells) tumors, intratumoral delivery of PTX-loaded
folate-targeted hybrid NPs showed lower toxicity but similar
antitumor efficacy compared with Taxol® and greater therapeutic efficacy than nontargeted NPs.75 To circumvent the
inherent limitations of cisplatin (chemotherapeutic) and ICG
(photothermal therapeutic) delivery, in 2016, Gu et al derived
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a folate-fabricated, cisplatin and ICG-loaded, homogeneous,
stable LPHNPs using PLGA, lecithin, DSPE–PEG2000, and
DSPE–PEG2000-FA by a single-step sonication method.
Targeting efficiency of the folate-modified NPs was greater
in folate receptor (FR) overexpressing MCF-7 cells than in
FR-negative A549 cells. Moreover, treatment of targeted
NPs with 808 nm near infra-red laser irradiation induced
substantial cell death by apoptosis and necrosis of MCF-7
cells compared with standard care therapy.76 Using an ESE
technique, a DOX-encapsulated LPHNP was constructed
with PLGA-lecithin-DSPE–PEG and further decorated with
DSPE–PEG-folate. It had been shown that folate-targeted
NPs confer higher uptake and cytotoxicity in MCF-7 cells
compared with nontargeted NPs.77 In order to bypass the
limitations of mitomycin C (a water-soluble antibacterial
and antitumor agent), it was complexed with soy-PC and
loaded onto a folate-functionalized LPHNP system having
a PLA core and DPPE/DSPE–PEG/DSPE–PEG-folate shell
using an ESE technique. Importantly, folate-decorated NPs
markedly improved pharmacokinetic profile (compared with
free drug) by extending circulation time and showed better
in vitro and in vivo therapeutic efficiency.78

Targeted delivery by RGD
Yang et al, in 2013, used a modified single ESE method
to produce an LPHNP with PLGA-EPC/DSPE–PEG and
DSPE–PEG-c(RGDyk) to deliver 10-hydroxycamptothecin
(HCPT) via targeting integrin α∨β3-positive cancer cells.
They optimized DSPE–PEG:EPC molar ratio to be 5:5 and
the lipids:PLGA mass ratio to be 1:15 with a zeta potential
of about -26 mV and with an average size of 230 nm. They
found an improved cytotoxicity profile of HCPT against
MDA-MB-435s cells for the targeted NPs.79 Using a double
ESE technique (w/o/w), RGD-functionalized polymer-core
lipid-shell hybrid NPs were synthesized by Zhao et al in 2013.
By the virtue of integrin recognition, these particles enhanced
cytotoxicity of curcumin in vitro and demonstrated tumor
growth inhibition and prolonged survival in a subcutaneous
B16 murine tumor model.80 To amend the poor bioavailability
of isoliquiritigenin (ISL), a natural antibreast cancer dietary
compound, Gao et al recently developed iRGD (tumorhoming peptide) decorated LPHNPs by a modified nanoprecipitation method using PLGA-lecithin/DSPE–PEG-Mal.
A postinsertion approach (iRGD covalently grafted onto the
PEG) was adopted to decorate the surface with iRGD peptides. Surface-functionalized ISL-loaded NPs demonstrated
better cytotoxicity and apoptotic cell death of different
types of breast cancer cells, prolonged in vivo circulation,
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and exhibited higher tumor growth inhibition efficacy in
4T1-bearing breast tumor murine models compared with
the free drug and nontargeted counterparts.81 In a separate
study, Shi et al developed RGD-modified LPHNPs for the
delivery of docetaxel to glioblastoma multiforme, from the
precursors PLGA-soy lecithin and DSPE–PEG (containing
DSPE–PEG2000-RGD and DSPE–PEG2000 at a molar ratio
of 8.5:1.5). After a series of experiments including cellular
uptake, tumor spheroid penetration, and tumor growth inhibition, a rat model of brain GBM was used to evaluate antitumor efficacy of the RGD-functionalized docetaxel-loaded
NPs where the median survival times for the rats treated with
these particles were prolonged by 57 days.82

Other methods for active targeting
Besides folate and RGD-mediated delivery, few attempts
have also been made using transferrin, antibodies, and aptamers to target cancer cells. For example, Zheng et al followed
a postinsertion method to develop a transferrin (Tf-DOPE)
conjugated LPHNPs encapsulating aromatase inhibitor
(7a-APTADD). Tf-conjugated NPs showed higher inhibition
of aromatase in breast cancer cells (SKBR-3) than that by
the nontargeted NPs.50 Again, Zhang et al covalently grafted
amine-terminated A10 RNA aptamer to carboxyl functionalized lipid–PEG conjugates in order to target prostate-specific
membrane antigen (PSMA) overexpressed in LNCaP cells.
Aptamer-conjugated NBD-encapsulated hybrid NPs were
successfully taken up by LNCaP via active-targeted mechanism but not by PC3 cells, which do not express PSMA.27
Utilizing single-step nanoprecipitation with the precursor
PLGA-soy lecithin-DSPE–PEG/DSPE–PEG-Mal, Hu et al
prepared a PTX-loaded LPHNP platform. A half-antibody
displaying anticarcinoembryonic activity was conjugated
to the hybrid NP via postinsertion to target carcinoembryonic antigen (CEA)-overexpressed pancreatic cancer cells.
Antibody-conjugated NPs, thus synthesized, were shown to
selectively target CEA-positive BxPC-3 pancreatic cancer
cells resulting in an elevated cellular uptake and higher
in vitro cytotoxicity compared with nontargeted NPs.83

siRNA delivery
RNAi is an evolutionarily conserved unique cellular surveillance mechanism, with sequence-specific post-transcriptional gene silencing capability. Ever since its disclosure in
cultured mammalian cells and mammals, studies aimed at
demonstrating the clinical potential of siRNAs have been
reported in mouse models as well as in nonhuman primates
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and more recently in humans.84 Global efforts have been
witnessed in developing vectors for in vivo delivery of
therapeutic siRNAs.85 Most recently, a lipid-based RNAi
therapeutic (ONPATTRO™, Alnylam Pharmaceuticals
Inc.) received FDA approval, which is the first of its category, for the treatment of polyneuropathy of hereditary
transthyretin-mediated amyloidosis in adults.86 Nevertheless,
a few cellular as well as preclinical studies have already been
performed for LPHNP-mediated RNAi. Here, we summarize
a few of them.
With the precursors PLGA-DOPC/cyclic cationic lipid
and DSPE−PEG2000, Desai et al formulated an LPHNP
through single-step nanoprecipitation to simultaneously
deliver an anti-inflammatory drug capsaicin and siRNA
against TNF-α (siTNFα) to treat skin inflammatory conditions under systemic settings. It was shown that the NPs
could deliver capsaicin deep into dermal tissue (~360 µm),
and its combination with siTNFα showed a synergistic effect
on skin inflammation.87 In 2012, with cationic lipid (N,Nbis(2-hydroxyethyl)-N-methyl-N-(2-cholesteryloxycarbonyl
aminoethyl) ammonium bromide, BHEM-Chol) and PLGA
polymers, LPHNPs were prepared by Yang et al for systemic
delivery of siRNA by a modified nanoprecipitation method.
NPs effectively delivered siPlk1 (targeted against Plk1 oncogene) to BT474 cells in vitro and BT474 xenograft murine
model in vivo and inhibited tumor growth.49 In another study,
siRNA was encapsulated within hybrid NPs prepared via
modified double emulsion solvent evaporation technique.
PLGA and a newly synthesized cationic lipid-like molecule
(G0-C14) were taken to constitute the core to which siRNA
was added and added together to DSPE–PEG and lecithin.
NP-mediated delivery of siPHB1, which outcompetes
standard lipofectamine complexes, resulted in long-term
silencing of the prohibitin 1 gene and therefore effective
tumor growth inhibition in vivo (A549 xenograft BALB/C
nude mice model).88 Intending to develop a well-capable
siRNA delivery platform, Shi et al proposed differentially
charged hollow core/shell LPHNPs made by modified double
emulsion solvent evaporation technique. Interestingly, GL3
siRNA encapsulated within these hybrid NPs was successfully delivered to luciferase-expressing xenograft tumors of
Dual-Luc HeLa cells and significantly reduced luciferase
activity.89 Another siRNA delivery platform was created
by Gao et al, wherein a cationic liposome made up of
DOTAP:DOPE:cholesterol (25:43:25) was mixed with the
anionic cholesterol-grafted poly(amidoamine)/siRNA, and
the resulting LPHNP was further modified with DSPE–PEG/
DSPE–PEG-T7 (where T7= HAIYPRH). Efficacy study on
nude mice bearing MCF-7 tumor xenografts further asserted
1948
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that T7-modified siEGFR-loaded NPs demonstrated highest
tumor growth inhibition via transferrin receptor-mediated
active-targeted delivery.90

Imaging agent delivery
In recent years, owing to its stability and biocompatibility,
LPHNPs have increasingly been used as a delivery system
for contrast agents (quantum dots, inorganic nanocrystals),
commonly used in bioimaging such as MRI and CT. For
instance, Mieszawska et al designed a unique method to
append diagnostic features to LPHNPs prepared via nanoprecipitation. They conjugated gold nanocrystals (AuNC)
and quantum dots to the PLGA by esterification reactions
and then mixed with soybean lecithin and PEG. The in vitro
experiments in mouse macrophage (J774A.1) further supported the suitability of AuNC and quantum dots-loaded
LPHNPs as probes for image generation in both biological
and medical settings.32 A parallel approach was to form
the core with polymers having high fluorescence. Using
nanoprecipitation, LPHNPs are synthesized where the core
is composed of PFBT with an envelope of DMPE–PEG.
Notably, hybrid NPs showed ~50% higher quantum yield
compared with their nonhybrid counterpart.53

Future possibilities
As evident from our prior discussion, one-step method is
preferred over the two-step method due to its simplicity.
Irrespective of the method of preparation, L/P ratio is found
to be the most crucial formulation parameter to monitor size,
homogeneity, %EE, release kinetics, while colloidal stability
is critically dependent on the steric stabilization provided by
the PEG fragment of the PEGylated lipid component. Subcategorically, within the realm of one-step method, despite
higher content loading in the ESE method, nanoprecipitation
is favored as it can produce sub-100 nm sized particles. Nanoprecipitation, thus, has advanced to large-scale production by
a continuous high-throughput microfluidic process. Research
endeavors in the near future will require an advancement of a
continuous high-throughput microfluidic process for the ESE
method as well. The ensuing challenge in large-scale production of LPHNPs, in common with all other scale-up processes, will be entrenching consistent production of particles
with controlled size and homogeneity. Another task required
for researchers in the field is to convert their liquid LPHNP
formulations to dry powder form, while keeping all physical
characteristics intact, which is essential for long-term storage. This has previously been explored for liposomes and
polymeric NPs.91,92 Conversion to dry powder, in general, is
executed by lyophilization or spray-drying in the presence
International Journal of Nanomedicine 2019:14
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of cryoprotectants. As is to be expected, optimizations of
formulation parameters are required while deciding the
method as well as the cryoprotectants.
Within the last 2 years, a number of new applications
for the LPHNP platform have been demonstrated. Notably,
these include photoresponsive LPHNPs for controlled release
of doxorubicin, insulin delivery, delivery of mRNA to lung
tissue, and MRI-guided targeted delivery of doxorubicin,
among others.93–97 Although the voyage is commenced, stepping out beyond the realm of oncology is still at the juvenile
stage for LPHNPs. Future directions of LPHNP research
remain open to translate its potential into practice for many
other disease models. For the delivery of genetic material, it is
essential to clarify the reduction of nonspecific binding with
serum proteins. Significant work is also required to establish
reliable clinical applications for the delivery of diagnostic
bioimaging agents. Advancements in clinical techniques for
minimally invasive targeted delivery may also further extend
the application of LPHNPs by maximizing therapeutic delivery and minimizing systemic exposure. One such approach,
called convection-enhanced delivery (CED), involves the
use of one or more microcatheters placed stereotactically
into target tissues (eg, intratumorally or within the target
brain regions) through which an infusate is actively pumped
while maintaining a pressure gradient over multiple hours.
A number of recent clinical trials using CED have shown
the technique to be an effective option for the delivery of
therapeutics with significantly greater volume of distribution vs standard diffusion-dependent delivery methods. As
such, CED holds great potential in current and future clinical
trial designs for improving the reliability of therapeutic
delivery and limiting confounding due to variable target
bioavailability. The combination of advanced minimally
invasive techniques like CED with the improved therapeutic
design offered by LPHNPs may offer synergistic potential
in future clinical applications and is an area of great interest
for future studies.98–100

Conclusion
LPHNPs have displayed a remarkable range of successes
in translating new clinical and drug delivery applications
from bench to bedside, with a significant and lasting impact
in the field of oncology. Indeed, in some cases, LPHNPs
have already demonstrated superiority compared with
liposomes and polymeric NPs. From the perspective of
industrial production and scalability, efficient and simple
large-scale production of NPs has already been developed.
As such, we predict ever-expanding applications for LPHNPs with many more translational opportunities for future
International Journal of Nanomedicine 2019:14
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clinical trials, including beyond active targeting of anticancer
therapies in oncology toward more broad applications in
medical therapies and neurotherapeutics as well as diagnostic
imaging agents.
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